ARDX ARDELYX, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of innovative medicines focused on tenapanor-based therapies for gastrointestinal and kidney diseases
• • New emphasis on Phase 3 trial initiation in January 2026 for tenapanor in chronic idiopathic constipation (CIC), targeting a new patient population of 34 million Americans

Risk Factors

• • Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
• • Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue

Management Discussion & Analysis

• • Total revenue $407.3M, up 22% YoY from $333.6M in 2024; product sales $377.8M, up 18% YoY from $319.2M
• • Operating expenses $448.3M, up 24% YoY from $361.6M; cost of sales down 22% to $39.5M vs $50.6M; R&D up 37% to $71.5M; SG&A up 30% to $337.2M

Risk Factors

• • New risk: XPHOZAH excluded from Medicare Part D as of January 1, 2025, shifting coverage to ESRD PPS, materially and negatively impacting revenue
• • Updated financial risk: Accumulated deficit widened to $946.5 million as of September 30, 2025, increasing pressure on achieving sustained cash flow positivity

What are the latest ARDX SEC filings in 2026?

ARDELYX, INC. (ARDX) has filed a 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ARDX file its most recent 10-K annual report?

ARDELYX, INC. (ARDX) filed its most recent 10-K annual report on February 19, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ARDX 10-Q quarterly reports?

ARDELYX, INC. (ARDX)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every ARDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ARDX filed recently?

ARDELYX, INC. (ARDX)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ARDX insider trading activity (Form 4)?

SignalX aggregates every ARDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ARDX file with the SEC?

ARDELYX, INC. (ARDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ARDX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ARDELYX, INC. (ARDX).

What is ARDX's SEC CIK number?

ARDELYX, INC. (ARDX)'s SEC CIK (Central Index Key) number is 1437402. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1437402 to look up all ARDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ARDX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ARDELYX, INC. (ARDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.